Mode
Text Size
Log in / Sign up
Phase 4 Completed N=162 Randomized Triple-blind Treatment

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine

Sleep
Source: ClinicalTrials.gov NCT01118273 ↗
Enrolled (actual)
162
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcomePrimary: Total Sleep Time Measured by Actigraphy — 339.80; 304.60; 413.89; 308.89 Minutes — p=0.54

Summary

The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and an ibuprofen and diphenhydramine combination

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Sleep Time Measured by Actigraphy
339.80; 304.60; 413.89; 308.89; 76.35; 335.68 0.54
SECONDARY
Wake After Sleep Onset (WASO) Measured by Actigraphy
139.96; 190.91; 75.66; 145.67; 428.34; 129.02 0.31
SECONDARY
Sleep Latency Measured by Actigraphy
29.17; 32.81; 46.77; 31.58; 41.05; 36.38 0.45
SECONDARY
Global Assessment of Study Medication as a Sleep-aid
1; 6; 2; 4; 6; 0 0.001 sig
SECONDARY
Karolinska Sleep Diary - Sleep Quality
1; 4; 1; 1; 1; 0 0.05
SECONDARY
Karolinska Sleep Diary - Calmness of Sleep
0; 2; 1; 1; 1; 0 0.019 sig
SECONDARY
Karolinska Sleep Diary - Easiness to Fall Asleep
0; 5; 1; 3; 1; 0 0.018 sig
SECONDARY
Karolinska Sleep Diary - Premature Awakening
5; 6; 2; 6; 8; 5 0.03 sig
SECONDARY
Karolinska Sleep Diary - Ease of Awakening
0; 1; 0; 1; 0; 0 0.76
SECONDARY
Karolinska Sleep Diary - Well Rested
1; 4; 0; 0; 3; 1 0.015 sig
SECONDARY
Karolinska Sleep Diary - Sufficient Sleep
1; 4; 0; 1; 2; 1 0.04 sig
SECONDARY
Total Sleep Time by Subject Assessment
306.32; 309.97; 339.08; 309.23; 160.49; 299.58 0.95
SECONDARY
Sleep Quality Index
3.49; 2.89; 3.40; 3.12; 2.96; 3.37 0.05
SECONDARY
Overall Rating of Severity in Categorical Pain Rating Scale Score
2.44; 2.48; 2.48; 2.48; 2.37; 2.22
SECONDARY
Change From Baseline in Categorical Pain Rating Scale Score
-1.2; -1.0; -1.2; -0.7; 0.3; -0.9 0.42
SECONDARY
Overall Rating of Severity in Visual Analog Scale (VAS) Score
76.11; 77.26; 78.19; 73.70; 79.15; 73.11 0.35
SECONDARY
Change From Baseline in Visual Analog Scale (VAS) Score
-44.04; -36.65; -47.26; -25.89; 6.00; -35.89 0.35
SECONDARY
Overall Rating of Pain Relief
1; 3; 2; 6; 11; 4 0.72
SECONDARY
Time to Rescue Medication
NA; NA; NA; NA; NA; NA 0.001 sig
SECONDARY
Cumulative Proportion of Participants Taking Rescue Medication by Hour
2; 3; 0; 1; 4; 0
SECONDARY
Global Assessment of Study Medication as a Pain Reliever
1; 4; 2; 6; 15; 5 0.35
SECONDARY
Number of Times Participants Took Rescue Medication
15; 15; 19; 14; 2; 16
SECONDARY
Total Wake Time Measured by Actigraphy
253.72; 290.03; 180.21; 285.62; 518.58; 255.20 0.53
SECONDARY
Sleep Efficiency Measured by Actigraphy
57.24; 51.49; 68.87; 52.09; 12.85; 56.70 0.55
SECONDARY
Activity Mean Measured by Actigraphy
42.09; 48.48; 26.73; 52.36; 72.43; 41.14 0.59
SECONDARY
Wake Episode Measured by Actigraphy
8.38; 10.86; 13.26; 9.89; 5.84; 11.98 0.25

Eligibility Criteria

Inclusion Criteria

  • Healthy, ambulatory, male and female volunteers between 16-45 years of age;
  • Scheduled to undergo surgical removal of 1 to 3 impacted third molars, one of which must be at least a partial bony mandibular impaction;
  • Have moderate to severe postoperative pain on the Categorical Pain Rating Scale and a score of >/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale by 2030 h +/- 15 minutes on the day of surgery;
  • Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g. oral or patch contraceptives, intrauterine device, Depo-Provera, or double-barrier and have a negative pregnancy test at Screening and prior to surgery. Female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy;
  • Provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial, (subjects <18 years of age must sign a written assent and have parental or guardian consent).

Exclusion Criteria

  • History of hypersensitivity to naproxen, diphenhydramine, nonsteroidal antiinflammatory drugs (NSAIDS), tramadol, aspirin or any other antihistamine and similar pharmacological agents or components of the products;
  • Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years;
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study in the judgment of the investigator;
  • Current or past history of bleeding disorder(s);
  • Acute illness or local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator;
  • Chronic use of antihistamines defined as using 5 or more times a week for 2 or more consecutive weeks during the past 3 months;
  • Positive alcohol breathalyzer test and negative urine drug test prior to surgery;
  • Females who are pregnant or lactating;
  • Chronic or severe sleep problems that do not respond to Over the counter (OTC) medication and requires a prescription hypnotic or sedative;
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01118273). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search